Artificial intelligence is touching all aspects of drug development with a lot of focus, and potential noise, on the early stages of drug discovery. In this episode of Bloomberg Intelligence’s Vanguards of Health podcast BI’s Head of Global Industries Sam Fazeli discusses the contributions of machine learning, AI and AlphaFold 3 in drug discovery with Harren Jhoti, cofounder of Astex in 1999. Jhoti remains CEO of the group as part of Otsuka Pharmaceuticals. Astex’s pioneering work in fragment-based drug discovery has lead to three marketed oncology drugs, including Novartis’ Kisqali used for breast cancer. We delve into the steps in which AI can have meaningful impact and what this may mean for saving time in drug development and reducing the risk of drug failure.